person · Reporting owner
Chinoporos Constantine
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | Director | March 25, 2026 | March 26, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Interim Chief Business Officer | July 16, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date March 25, 2026 · Filed March 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2036-03-24 | Direct | 270,000 |
Reported balance
After 2026-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 270,000 · Balance 270,000 F1: The option shall vest and become exercisable in three equal annual installments starting on March 25, 2027, subject to the Reporting Person's continuous service (as defined in the Issuer's 2018 Equity Incentive Plan) with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in three equal annual installments starting on March 25, 2027, subject to the Reporting Person's continuous service (as defined in the Issuer's 2018 Equity Incentive Plan) with the Issuer through each such vesting date.
enGene Therapeutics Inc.
Report date July 16, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Therapeutics, Inc.
Report date December 19, 2025 · Filed February 04, 2026
Section 16 reporting ended · disclosed 2026-02-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,057,111 |
Reported balance
After 2025-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 437,500 · Balance 1,057,111 F1: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date. F2: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings. |
| Common StockSEC Table I · non-derivative | Direct | 57,111 |
Reported balance
After 2026-02-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-03 · Disposition to issuer · Disposed 1,000,000 · Balance 57,111 F3: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-03 · Other · Disposed 57,111 · Balance 0 F3: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F5: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.
F2: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.
F3: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F5: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 26, 2026 21:37 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0002014509-26-000003 · form4-03262026_090305.xml · derivative · entry 1 Chinoporos Constantine · CIK 0002014509 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The option shall vest and become exercisable in three equal annual installments starting on March 25, 2027, subject to the Reporting Person's continuous service (as defined in the Issuer's 2018 Equity Incentive Plan) with the Issuer through each such vesting date. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 00:03 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | OtherCommon Stock | 57,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036176 · ownership.xml · nonDerivative · entry 3 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F5 · kind: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. F5 · price: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 00:03 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036176 · ownership.xml · nonDerivative · entry 2 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,111 F3 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. F3 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Read SEC document |
| December 19, 2025 Filed Feb 4, 2026 00:03 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 437,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036176 · ownership.xml · nonDerivative · entry 1 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,057,111 F1 · kind: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date. F2 · balance_after: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 00:14 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-045609 · ownership.xml · nonDerivative · entry 1 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,436 F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. One fourth (1/4th) of the compensatory RSUs shall vest on March 24, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory RSUs shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:30 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 447 | $0.44 | $196.68 |
DisclosureSEC source: 0000950170-25-035040 · ownership.xml · nonDerivative · entry 1 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,436 F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:30 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 28,117 | $0.61 | $17,151.37 |
DisclosureSEC source: 0000950170-25-016585 · ownership.xml · nonDerivative · entry 1 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,883 F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 28, 2023 Filed Mar 18, 2024 21:51 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001096906-24-000489 · form4.xml · nonDerivative · entry 1 Chinoporos Constantine · CIK 0002014509 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 28, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.